The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Alk-Abello AS's Revenue for the
three
months ended in Mar. 2026 was kr1,771 Mil. Alk-Abello AS's average Accounts Receivable for the
three
months ended in Mar. 2026 was kr1,071 Mil.
Hence, Alk-Abello AS's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.65.
Alk-Abello AS (CHIX:ALKBc) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Alk-Abello AS Receivables Turnover Related Terms
Alk-Abello AS Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Alk-Abello AS's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:ALKBC vs VRTX, REGN, ALNY: Receivables Turnover Comparison
For the Biotechnology subindustry, Alk-Abello AS's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alk-Abello AS Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alk-Abello AS's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Alk-Abello AS's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alk-Abello AS (CHIX:ALKBC) has a Receivables Turnover of 1.65 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Alk-Abello AS and its competitors. According to the industry distribution chart, Alk-Abello AS ranks #331 out of 840 companies in the Biotechnology industry, placing it in the top 39.4%.
Is Alk-Abello AS's Receivables Turnover too high?
Alk-Abello AS's current Receivables Turnover is 1.65. The Biotechnology industry median Receivables Turnover is 5.30. Alk-Abello AS's value of 1.65 is 68.9% below this industry median. Based on the distribution chart, Alk-Abello AS ranks #331 out of 840 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Alk-Abello AS has a GF Score™ of 92/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alk-Abello AS's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alk-Abello AS ranks #331 out of 840 companies for Receivables Turnover. This puts Alk-Abello AS in the upper half of its industry. The industry median Receivables Turnover is 5.30. Alk-Abello AS's value of 1.65 is 68.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.30, based on 840 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alk-Abello AS's current Receivables Turnover of 1.65 is 68.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Alk-Abello AS and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alk-Abello AS's current Receivables Turnover is 1.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alk-Abello AS stock overvalued right now?
Based on GuruFocus' analysis, Alk-Abello AS (CHIX:ALKBC) is currently considered Modestly Overvalued. The stock's GF Value™ is kr207.94, compared to a current price of kr256.30 — trading 23.3% above its estimated fair value. The current Receivables Turnover is 1.65 and 68.9% below the Biotechnology industry median of 5.30. Alk-Abello AS's overall GF Score™ is 92/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Alk-Abello AS (CHIX:ALKBC), the current Receivables Turnover is 1.65 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alk-Abello AS (CHIX:ALKBC) Overvalued in 2026?
Based on GuruFocus' analysis, Alk-Abello AS stock appears to be overvalued.
The current stock price of kr256.30 is trading 23.3% above its estimated GF Value™ of kr207.94.
GuruFocus considers Alk-Abello AS to be Modestly Overvalued.
Key valuation signals for CHIX:ALKBC:
Receivables Turnover: 1.65
GF Value™: kr207.94 vs. price of kr256.30 (23.3% above fair value)
Industry Position: 68.9% below the Biotechnology median (#331 of 840)
No single metric tells the full story. See the CHIX:ALKBC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.
92GF Score
Get the complete analysis for CHIX:ALKBC
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:ALKBC has been successfully added to your 
